Acrivon logo.jpg
Acrivon Therapeutics to Present Data Demonstrating Deployment of its AP3 Platform for Streamlined Drug Discovery and Clinical Development at Two Scientific Conferences - Human Proteome Organization World Congress and EORTC-NCI-AACR Symposium
October 17, 2024 08:00 ET | Acrivon Therapeutics, Inc
AP3-identified clinical biomarkers for ACR-368 led to the development of a response-predictive OncoSignature assay which has shown statistically significant prospective validation and responder...
Acrivon logo.jpg
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
October 16, 2024 16:00 ET | Acrivon Therapeutics, Inc
WATERTOWN, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage precision medicine company utilizing its Acrivon...
Acrivon logo.jpg
Acrivon Therapeutics Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent Activity
October 11, 2024 08:00 ET | Acrivon Therapeutics, Inc
- First patient dosed two quarters ahead of original timelines in Acrivon Phase 1 study to assess safety and tolerability of ACR-2316 - ACR-2316 was internally discovered and advanced in 15 months...
Acrivon logo.jpg
Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data Analysis
September 14, 2024 03:10 ET | Acrivon Therapeutics, Inc
Confirmed overall response rate (ORR) = 62.5% (95% CI, 30.4-86.5) observed in prospectively-selected ACR-368 OncoSignature-positive (BM+) patients with endometrial cancer Achieved statistically...
Acrivon logo.jpg
Acrivon Therapeutics to Present at the Cantor Global Healthcare Conference
September 10, 2024 08:00 ET | Acrivon Therapeutics, Inc
WATERTOWN, Mass., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage precision medicine company utilizing its...
Acrivon logo.jpg
Acrivon Therapeutics to Host Virtual Investor Event to Review Positive Phase 2 Clinical Data of ACR-368 Presented at ESMO and Pipeline Progress, Including Clinical Candidate ACR-2316
September 09, 2024 07:00 ET | Acrivon Therapeutics, Inc
-Webcast investor event on September 14, 2024 at 9:00 a.m. ET -ESMO poster presentation to provide updated ACR-368 clinical data in endometrial cancer -Webcast to provide updates on its lead assets...
Acrivon logo.jpg
Acrivon Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights
August 13, 2024 08:00 ET | Acrivon Therapeutics, Inc
WATERTOWN, Mass., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage precision medicine company utilizing its Acrivon...
Acrivon logo.jpg
Acrivon Therapeutics to Present at the Jefferies Global Healthcare Conference
May 29, 2024 08:00 ET | Acrivon Therapeutics, Inc
WATERTOWN, Mass., May 29, 2024 (GLOBE NEWSWIRE) --  Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision...
Acrivon logo.jpg
Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
May 14, 2024 08:00 ET | Acrivon Therapeutics, Inc
WATERTOWN, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision...
Acrivon logo.jpg
Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D Event
April 24, 2024 16:01 ET | Acrivon Therapeutics, Inc
•  Initial ACR-368 Phase 2b clinical data in patients with ovarian or endometrial cancers (n=26; 10 OncoSignature-positive and 16 OncoSignature-negative) are being presented•  A 50% confirmed overall...